Clinical Trials Directory

Trials / Completed

CompletedNCT00773136

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

Effect of Bimatoprost (Lumigan) in Gel Suspension Applied to the Eyelashes on Eyelash Growth

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
21 (actual)
Sponsor
University of Miami · Academic / Other
Sex
All
Age
20 Years – 90 Years
Healthy volunteers
Accepted

Summary

Objective: To determine if Lumigan (bimatoprost) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened and those who met inclusion criteria were enrolled. Each participant received two vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with GonakTM gel and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the eyelashes every evening on the designated eye for 6 weeks. Lash length was measured with a caliper at enrollment, at weekly intervals during the study and at 1 and 3 months after study completion. Visual acuity, ocular symptoms, intraocular pressure and photographs were documented at these same intervals. Results: The average eyelash growth in the Lumigan group was 2.01mm (vs. control average of 1.13mm) which was a statistically significant difference (p=0.009). The average intraocular pressure decreased equally in both groups (2.14 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Discussion: Our data showed an increase in eyelash length with use of Lumigan in gel suspension, suggesting that it may have eyelash lengthening properties.

Detailed description

Study completed

Conditions

Interventions

TypeNameDescription
DRUGBimatoprost Suspensionsee prior

Timeline

Start date
2008-02-01
Primary completion
2008-07-01
Completion
2008-07-01
First posted
2008-10-16
Last updated
2014-04-16
Results posted
2014-04-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00773136. Inclusion in this directory is not an endorsement.